论文部分内容阅读
单用维生素 K_1(VK_1)甚至是大剂量,对治疗失代偿期肝硬化的出血倾向无效。因为在有胆汁酸存在的情况下,VK_1在小肠内的吸收较好,作者对35例肝硬化失代偿有出血倾向的患者,采用 VK_1及合用胆汁酸进行对照治疗研究。将35例失代偿肝硬化伴有出血倾向的患者分为4组:①组单用 VK_1,每天60mg;②组每天用 VK_160mg 和熊去氧胆酸(UDCA)300mg;③组每天给 VK_160mg 和鹅去氧胆酸(UDCA)300mg;④组每天给VK_160mg 和人造脂肪24g。治疗前后测定患者的肝凝
Vitamin K_1 (VK_1), alone or in large doses, is ineffective in treating bleeding in decompensated cirrhosis. Because VK_1 is well absorbed in the small intestine in the presence of bile acids, the authors conducted a controlled study of 35 patients with bleeding-prone cirrhosis who had a tendency to bleed. 35 patients with decompensated liver cirrhosis with bleeding tendency were divided into 4 groups: ① group with VK_1, daily 60mg; ② group daily with VK 160mg and ursodeoxycholic acid (UDCA) 300mg; ③ group daily VK 160mg and Chenodeoxycholic acid (UDCA) 300mg; ④ group VK 160mg and artificial fat 24g daily. Before and after treatment in patients with liver coagulation